84 terminated. 84 Phase 2, 34 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 84 | Terminated 84 |
| Phase 1 | 34 | Terminated 34 |
| Phase 3 | 2 | Terminated 2 |
Follow Acute Myeloid Leukemia: new trials by email Literature Review of Acute Myeloid Leukemia trials Research Report on Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multiple CAR-T Cell Therapy Targeting AML CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2025-08-01 | 2026-11-02 |
| A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies SAR443579, venetoclax, azacitidine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Sanofi | 7 | 2024-08-13 | 2026-10-19 |
| Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia Clofarabine, Fludarabine, Hematopoietic Cell Transplantation - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 23 | 2023-08-11 | 2026-08-06 |
| A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant Siremadlin - Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 8 | 2023-02-23 | 2025-05-16 |
| Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers Fludarabine, Cyclophosphamide, Thiotepa - Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2022-10-06 | 2025-01-01 |
| ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML) TCB008 - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | Terminated | TC Biopharm | 16 | 2022-08-15 | 2025-09-30 |
| A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) Lanraplenib, Gilteritinib - Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Kronos Bio | 24 | 2022-08-05 | 2024-08-07 |
| Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients Venetoclax, Azacitidine, Venetoclax, daunorubicin, cytarabine - Acute Myeloid Leukemia, Measurable Disease | Phase 2 | Terminated | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2022-06-29 | 2025-12-05 |
| Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission Cytarabine - Acute Myeloid Leukemia | Phase 2 | Terminated | University of Florida | 5 | 2022-03-08 | 2025-01-16 |
| Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia Arm 1: NTLA-5001, Arm 2: NTLA-5001 - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Intellia Therapeutics | 6 | 2021-12-17 | 2023-12-28 |
| Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. Sabatolimab, Azacitidine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 24 | 2021-09-14 | 2025-10-16 |
| Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Tamibarotene, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 2 | Terminated | Syros Pharmaceuticals | 66 | 2021-08-26 | 2025-02-24 |
| CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2021-08-09 | 2024-05-23 |
| Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia tagraxofusp - Acute Myeloid Leukemia | Phase 2 | Terminated | Gruppo Italiano Malattie EMatologiche dell'Adulto | 25 | 2021-02-16 | 2025-01-30 |
| Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Enasidenib, Venetoclax - Acute Myeloid Leukemia, Relapsed Cancer | Phase 1 / Phase 2 | Terminated | University Health Network, Toronto | 27 | 2020-11-05 | 2024-01-24 |
| Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant MT-401 - Acute Myeloid Leukemia, Stem Cell Transplantation | Phase 2 | Terminated | Marker Therapeutics, Inc. | 92 | 2020-10-14 | 2025-10-30 |
| A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy MBG453, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 2 | Terminated | Novartis Pharmaceuticals | 90 | 2020-09-01 | 2026-01-13 |
| Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia Azacitidine, Magrolimab, Venetoclax - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 110 | 2020-07-28 | 2026-04-23 |
| Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML Clofarabine, Fludarabine, Busulfan - Acute Myeloid Leukemia | Phase 2 | Terminated | Milton S. Hershey Medical Center | 2 | 2020-06-03 | 2023-09-14 |
| AflacLL1901 (CHOA-AML) Cytarabine, Daunorubicin, Erwinase - Acute Myeloid Leukemia, AML, Childhood | Phase 2 | Terminated | Emory University | 8 | 2020-01-24 | 2022-06-15 |
Showing 20 of 84. Sign in to see all of them.
Leukemia, Myeloid, Acute (84) · Myelodysplastic Syndromes (20) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (16) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (9) · Leukemia (8) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Non-Hodgkin (5) · Multiple Myeloma (5) · Recurrence (5) · Primary Myelofibrosis (4) · Anemia, Refractory, with Excess of Blasts (3) · Hematologic Diseases (3) · Hodgkin Disease (3) · Leukemia, Biphenotypic, Acute (3) · Leukemia, Myelomonocytic, Chronic (3)
Hemic and Lymphatic Diseases (84) · Leukemia, Myeloid (84) · Neoplasms by Histologic Type (84) · Hematologic Diseases (81) · Neoplasms (81) · Leukemia (76) · Bone Marrow Diseases (24) · Pathologic Processes (21) · Pathological Conditions, Signs and Symptoms (21) · Disease Attributes (20) · Immune System Diseases (20) · Immunoproliferative Disorders (20) · Lymphoproliferative Disorders (20) · Lymphatic Diseases (19) · Leukemia, Lymphoid (18)
Cytarabine (22) · Azacitidine (12) · fludarabine (9) · venetoclax (9) · Cyclophosphamide (8) · Daunorubicin (8) · Clofarabine (5) · Decitabine (5) · Stem Cell Transplantation (5) · Whole-Body Irradiation (5) · Etoposide (4) · Mitoxantrone (4) · fludarabine phosphate (4) · Antilymphocyte Serum (3) · Asparaginase (3)
Fred Hutchinson Cancer Center (6) · M.D. Anderson Cancer Center (6) · Novartis Pharmaceuticals (4) · Technische Universität Dresden (3) · Astex Pharmaceuticals, Inc. (2) · Bellicum Pharmaceuticals (2) · Masonic Cancer Center, University of Minnesota (2) · Medical College of Wisconsin (2) · Sanofi (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University Health Network, Toronto (2) · University of Florida (2) · Washington University School of Medicine (2) · AGC Biologics S.p.A. (1) · Abramson Cancer Center at Penn Medicine (1)
United States (65) · Germany (11) · Italy (10) · Spain (9) · France (7) · Canada (6) · United Kingdom (5) · Australia (4) · South Korea (4) · Sweden (4) · Czechia (3) · Denmark (3) · Netherlands (3) · Taiwan (3) · China (2)
Filippo Milano (2) · Abhishek Maiti, MBBS (1) · Alexandra Gomez Arteaga, MD (1) · Allen R. Chen, MD,PhD. MHS (1) · Amer M Zeidan, MBBS (1) · Andrea Bacigalupo, Prof (1) · Andrew Gilman, MD (1) · Angela Smith, M.D. (1) · Aude Chapuis (1) · Courtney DiNardo, MD (1)
PMID 24200998, PMID 24355079, PMID 29296761, PMID 30542286, PMID 32476546, PMID 32683126, PMID 32896301, PMID 33027528, PMID 33091124, PMID 33554732, PMID 33580980, PMID 33792630, PMID 34255353, PMID 34474640, PMID 34807983, PMID 37386016, PMID 38548404, PMID 38841781, PMID 41043099, PMID 41075807, PMID 42761251
2018 (3), P30CA015704 (3), 2008 (1), 2014 (1), 2016 (1), 2019 (1), 2023 (1), P01CA018029 (1), P01CA078902 (1), P30CA072720 (1), P50CA171963 (1), R34HL142322 (1), UM1CA186712 (1)